technolog
advanc
immunolog
protein
design
genet
deliveri
unlock
new
possibl
vaccin
concept
deliveri
technolog
previous
inaccess
nextgener
vaccin
design
effort
particularli
promis
potenti
provid
solut
challeng
target
convent
approach
proven
ineffectivefor
exampl
univers
influenza
vaccin
perspect
discuss
emerg
approach
vaccin
design
engin
base
recent
insight
immunolog
structur
biolog
comput
biolog
immunoengin
anticip
cuttingedg
interdisciplinari
approach
lead
breakthrough
vaccin
concept
everevolv
emerg
influenza
virus
import
ramif
global
public
health
last
year
immens
effort
devot
understand
influenza
virus
yield
deeper
understand
viral
pathogenesi
anim
model
infect
innat
adapt
immun
respons
viru
origin
antigen
sin
immunodomin
antigen
imprint
among
number
achiev
deploy
influenza
vaccin
import
mileston
save
countless
live
date
major
breakthrough
knowledg
humor
immun
respons
influenza
viru
discoveri
broadli
neutral
antibodi
bnab
target
structur
function
conserv
site
vulner
viral
hemagglutinin
ha
furthermor
sever
appar
common
lineag
bnab
identifi
across
multipl
individu
find
instruct
us
development
pathway
could
lead
bnab
respons
influenza
breath
new
life
effort
design
vaccin
protect
wide
varieti
viru
strain
univers
influenza
vaccin
effort
driven
technolog
revolut
sever
field
made
possibl
new
approach
vaccin
design
deliveri
provid
perspect
prospect
next
gener
influenza
vaccin
base
new
approach
concept
although
major
univers
influenza
vaccin
effort
direct
subunit
vaccin
altern
platform
sever
new
concept
viru
manipul
current
evalu
liveattenu
vaccin
format
orthodox
approach
gener
attenu
viru
vaccin
often
involv
serial
passag
virus
vitro
vivo
exampl
first
report
liveattenu
influenza
vaccin
gener
adapt
viru
success
lower
temperatur
result
coldadapt
viru
remain
basi
current
commerci
liveattenu
influenza
vaccin
howev
sever
orthogon
approach
synthet
attenu
virus
explor
exampl
introduct
condit
defect
influenza
ha
engin
posttransl
process
matur
demonstr
effect
viru
attenu
strategi
engin
ha
possess
proteolyt
cleavag
site
recogn
pancreat
elastas
instead
trypsinlik
serin
proteas
result
viru
highli
attenu
remain
immunogen
viru
attenu
genomewid
modif
codon
pair
bia
adjac
codon
usag
deoptim
without
introduc
nonsynonym
mutat
initi
demonstr
polioviru
later
proven
efficaci
influenza
virus
precis
mechan
approach
viru
attenu
may
relat
ineffici
translat
disfavor
codon
pair
trigger
innat
immun
sensor
coincident
increas
frequenc
cpgupa
dinucleotid
combin
two
incorpor
microrna
mirna
respons
element
viral
genom
alter
tissu
tropism
andor
restrict
host
speci
rang
also
explor
attenu
strategi
anoth
approach
recod
influenza
genom
includ
amber
codon
tag
certain
circumst
translat
unnatur
amino
acid
uaa
eg
n
viru
modif
propag
engin
cell
line
express
trna
cua
uaa
yet
fulli
immunogen
errorpron
natur
viral
rnadepend
rna
polymeras
offer
anoth
sophist
way
attenu
virus
via
redirect
evolut
sequenc
space
recent
exampl
coxsacki
influenza
virus
recod
includ
codon
singl
nucleotid
substitut
away
stop
codon
recod
virus
highli
sensit
mutagen
condit
highli
attenu
vivo
retain
capac
immun
induct
advanc
candid
use
orthogon
viral
attenu
method
incorpor
specif
mutat
known
disrupt
viral
interferon
suppress
mechan
result
stronger
type
interferon
ifni
respons
infect
cell
import
note
concept
make
viru
suscept
innat
immun
henc
attenu
virul
also
enhanc
immunogen
provid
transient
milieu
absenc
inflammatori
cytokin
help
enhanc
adapt
immun
mani
recent
advanc
vaccin
develop
driven
structur
antibodi
target
often
complex
inform
approach
aim
elicit
desir
respons
use
design
immunogen
figur
addit
advanc
experiment
structur
biolog
method
comput
model
design
protein
becom
increasingli
power
enabl
ration
approach
highli
complex
problem
protein
engin
howev
singl
best
solut
design
immunogen
diseas
differ
pathogen
use
divers
strategi
evad
protect
immun
respons
vaccin
design
strategi
must
tailor
knowledg
protect
antibodi
function
diseas
particular
antigen
may
may
elicit
mani
antigen
adopt
multipl
conform
state
throughout
life
cycl
pathogen
either
part
natur
function
explicit
strategi
immun
evas
antigen
stabil
desir
antigen
state
conceptu
straightforward
approach
improv
qualiti
antibodi
respons
common
problem
encount
express
antigen
outsid
nativ
context
fail
adopt
correct
quaternari
structur
eg
ectodomain
envelop
viru
glycoprotein
express
without
nativ
transmembran
domain
genet
fusion
multimer
protein
scaffold
higher
stabil
proven
gener
method
quaternari
stabil
antigen
usual
perform
use
protein
complex
symmetri
match
antigen
rang
small
scaffold
foldon
trimer
domain
fibritin
larger
multim
ferritin
display
multipl
copi
oligomer
antigen
often
requir
product
stabl
antigen
heterolog
multimer
domain
gener
address
sourc
instabl
unrel
quaternari
structur
exampl
mani
viral
glycoprotein
type
conform
heterogen
problemat
metast
prefus
state
desir
antigen
exagger
antigen
recombinantli
express
purifi
isol
detail
knowledg
desir
undesir
structur
state
precis
techniqu
protein
engin
design
use
favor
disfavor
specif
conform
target
protein
common
strategi
includ
design
disulfid
bond
immobil
link
domain
improv
hydrophob
pack
stabil
particular
conform
state
prolin
mutat
constrain
conform
flexibl
prolineglycin
mutat
discourag
helix
format
one
wellcharacter
exampl
fab
potent
prefusionspecif
neutral
antibodi
fusion
glycoprotein
respiratori
syncyti
viru
rsv
f
use
combin
foldon
trimer
domain
c
terminu
maintain
f
metast
prefus
conform
prevent
irrevers
transit
postfus
state
solv
structur
prefus
state
complex
fab
mutat
introduc
disulfid
bond
cavityfil
hydrophob
side
chain
made
f
stabil
protein
conform
design
prefusionstabil
antigen
elicit
much
stronger
neutral
antibodi
respons
postfus
f
current
evalu
phase
clinic
trial
addit
prefusionstabil
rsv
f
antigen
gener
introduc
prolin
mutat
discontinu
helic
form
continu
helix
upon
transit
postfus
structur
approach
also
use
stabil
viral
glycoprotein
spike
protein
middl
east
respiratori
syndrom
coronaviru
mer
cov
sever
acut
respiratori
syndrom
sar
cov
human
cov
hiv
combin
disulfid
prolin
mutat
shown
stabil
solubl
version
env
glycoprotein
trimer
nativelik
prefus
conform
extens
design
strategi
gener
across
env
glycoprotein
mani
differ
strain
becom
invalu
tool
vaccin
develop
studi
humor
respons
viru
stabil
strategi
proven
immens
use
gener
conform
homogen
antigen
intact
molecul
continu
develop
applic
method
applic
mani
vaccin
design
context
anoth
major
challeng
antigen
design
develop
strategi
elicit
broadli
protect
respons
antigen
variabl
virus
influenza
hiv
mani
approach
current
evalu
preclin
research
begin
enter
clinic
trial
one
intuit
appeal
approach
focu
immun
respons
epitop
conserv
across
multipl
viru
strain
subtyp
clade
speci
concept
support
observ
bnab
mani
pathogen
target
precis
epitop
howev
design
strategi
must
overcom
presenc
less
conserv
distract
epitop
either
strainspecif
incap
elicit
protect
respons
inspir
widespread
viral
immun
evas
mechan
physic
mask
antigen
surfac
immunodomin
head
domain
influenza
ha
use
hyperglycosyl
shown
redirect
antibodi
respons
desir
epitop
case
subdomainbas
approach
remov
element
contain
undesir
epitop
antigen
entir
also
wide
employ
focu
immun
respons
case
simpl
elimin
undesir
portion
antigen
usual
along
domain
boundari
use
produc
minim
antigen
structur
antigen
intact
case
complex
manipul
novel
loop
connect
stabil
mutat
requir
headless
stabil
stem
lack
immunodomin
head
region
success
exampl
shown
induc
respons
immunolog
subdomin
stem
broader
crossreact
similarli
radic
delet
loop
connect
stabil
mutat
use
produc
minim
version
bind
site
hiv
env
call
eod
proven
robust
platform
engin
discuss
extrem
variat
subdomain
approach
known
epitopefocus
vaccin
design
use
gener
antigen
present
specif
welldefin
epitop
known
target
neutral
antibodi
sever
exampl
demonstr
comput
protein
design
use
incorpor
epitop
unrel
scaffold
protein
high
structur
fidel
epitop
scaffold
bind
target
antibodi
high
affin
upon
immun
induc
antibodi
bind
nativ
antigen
case
neutral
pathogen
anoth
flavor
epitopefocus
vaccin
design
conserv
linear
epitop
target
neutral
antibodi
fusion
peptid
hiv
env
present
antigen
multival
display
platform
structureagnost
manner
epitopefocus
vaccin
design
offer
conceptu
framework
target
desir
epitop
high
precis
induc
high
level
neutral
antibodi
minim
epitopebas
antigen
challeng
risk
immun
evas
approach
typic
target
singl
vulner
epitop
combin
epitopefocus
design
continu
explor
optim
multival
present
platform
discuss
could
help
address
issu
control
use
antigen
variat
anoth
strategi
highlight
conserv
region
immun
respons
exampl
heterolog
primeboost
strategi
use
administ
antigen
significantli
vari
offtarget
region
undesir
epitop
keep
desir
epitop
invari
across
antigen
maxim
respons
region
process
enhanc
design
antigen
optim
purpos
exemplifi
chimer
ha
antigen
head
region
ha
season
circul
viru
replac
correspond
region
exot
subtyp
human
never
encount
combin
lowlevel
preexist
immun
conserv
stem
epitop
sequenti
administr
antigen
distinct
head
region
preexist
immun
exist
strategi
aim
maxim
stemdirect
respons
current
evalu
clinic
trial
target
conserv
epitop
promis
strategi
elicit
broadli
protect
respons
differ
surround
motif
epitop
conform
strain
imped
crossreact
immun
influenza
particularli
true
receptorbind
site
rb
mani
mutat
near
rb
significantli
limit
breadth
known
crossreact
antibodi
region
stemdirect
respons
inher
broader
due
higher
conserv
region
ha
yet
remain
challeng
elicit
strong
antistem
respons
span
group
group
influenza
virus
ideal
protect
influenza
b
virus
achiev
univers
protect
divers
collect
virus
epitopefocus
strategi
must
optim
cater
toward
maxim
breadth
differ
approach
induc
bnab
immun
refer
germlinetarget
lineagebas
vaccin
design
inspir
evergrow
collect
bnab
hiv
influenza
identif
structur
genet
constraint
bnab
develop
commonli
found
across
multipl
individu
enabl
highthroughput
antibodi
sequenc
technolog
provid
system
classifi
bnab
made
idea
target
particular
class
viabl
option
vaccin
design
central
concept
lineagebas
vaccin
design
design
antigen
strongli
bind
infer
unmut
precursor
known
class
bnab
potenti
drive
direct
elicit
bnab
respons
strategi
establish
context
hiv
vaccin
research
primarili
though
focus
elicit
bnab
bind
site
hiv
env
lead
exampl
antigen
extens
engin
high
affin
unmut
common
ancestor
bnab
display
multival
fashion
selfassembl
protein
scaffold
success
activ
target
precursor
b
cell
knockin
mous
model
recent
advanc
proofofconcept
studi
human
signific
room
explor
applic
strategi
virus
hiv
particularli
influenza
grow
knowledg
multidonor
class
bnab
could
target
lineagebas
approach
may
enabl
elicit
specif
class
antibodi
design
antigen
tailor
bia
specif
antibodi
respons
pattern
polyclon
level
well
case
complex
antigen
varieti
epitop
could
mediat
neutral
protect
approach
combin
multipl
sequenc
divers
strain
consensu
geneticmosa
sequenc
present
epitop
includ
strain
potenti
induc
broad
respons
influenza
concept
evalu
use
comput
optim
broadli
reactiv
antigen
design
strategi
focus
head
region
ha
intent
maxim
breadth
hemagglutin
inhibit
hai
titer
success
improv
crossreact
within
individu
subtyp
influenza
similar
approach
use
hiv
vaccin
develop
produc
env
trimer
compos
varieti
sequenc
divers
polyclonalcent
strategi
recent
combin
lineagebas
vaccin
design
case
germlinetarget
mutat
ad
two
distinct
epitop
sosip
trimer
activ
unmut
common
ancestor
two
class
bnab
strategi
valid
knockin
mice
look
ahead
coordin
design
coadministr
multipl
antigen
could
promis
approach
increas
breadth
virus
exhibit
extrem
structur
antigen
divers
influenza
hiv
particular
design
antigen
specif
intend
codeliv
multimer
display
may
promis
avenu
futur
investig
manner
antigen
present
immun
system
profoundli
influenc
ensu
respons
recent
technolog
advanc
enabl
new
approach
antigen
display
deliveri
increas
potenc
durabl
vaccin
respons
optim
balanc
humor
cellular
immun
figur
focu
two
technolog
selfassembl
protein
multival
antigen
display
platform
genet
immun
via
mrna
vaccin
although
way
may
specif
materi
platform
signific
limit
earli
display
platform
inabl
scaffold
complex
antigen
intact
ectodomain
viral
glycoprotein
discoveri
nonvir
selfassembl
protein
ferritin
lumazin
synthas
form
monodispers
immunogen
present
larg
complex
antigen
recent
move
field
beyond
limit
small
set
protein
use
present
wide
varieti
antigen
includ
deriv
influenza
hiv
epsteinbarr
viru
studi
multival
display
consist
robustli
enhanc
potenc
antigenspecif
respons
case
selfassembl
scaffold
success
combin
antigen
design
focu
respons
specif
epitop
therefor
improv
neutral
potenc
breadth
firstinclass
clinic
trial
selfassembl
nanoparticlebas
influenza
vaccin
recent
start
selfassembl
protein
sever
advantag
multival
antigen
present
platform
seamless
integr
antigen
selfassembl
scaffold
via
genet
fusionan
approach
uniqu
selfassembl
protein
scaffoldsfacilit
immunogen
product
recombin
antigen
product
antigen
scaffold
accomplish
singl
molecul
altern
simpl
robust
gentl
proteinbas
conjug
system
spycatcherspytag
enabl
rapid
prototyp
mani
differ
antigen
selfassembl
protein
scaffold
approach
dub
pluganddisplay
function
protein
fold
assembl
welldefin
uniqu
low
energi
state
selfassembl
protein
immunogen
tend
highli
order
monodispers
make
easier
character
qualiti
potenc
heterogen
materi
note
selfassembl
scaffold
also
stabil
antigen
nativ
oligomer
state
furthermor
fact
selfassembl
protein
genet
encod
open
possibl
deploy
potent
nanoparticl
immunogen
via
genet
immun
eg
viral
vector
nucleic
acid
vaccin
see
howev
unlik
polymer
system
liposom
potenti
liabil
use
selfassembl
protein
scaffold
result
immunogen
tend
induc
antibodi
respons
scaffold
gener
prevent
elicit
potent
antigenspecif
respons
remain
seen
whether
engin
mechan
dampen
avoid
antiscaffold
respons
system
might
improv
antigenspecif
protect
respons
look
ahead
limit
number
exist
selfassembl
protein
scaffold
fact
structur
properti
essenti
fix
sever
constrain
design
space
may
explor
recent
new
comput
method
develop
design
novel
selfassembl
protein
atomiclevel
accuraci
method
enabl
gener
new
protein
scaffold
structur
featur
size
shape
number
subunit
locat
orient
display
antigen
systemat
precis
control
expect
studi
improv
understand
structur
correl
immunogen
gener
potent
new
vaccin
candid
first
exampl
use
comput
design
selfassembl
protein
vaccin
scaffold
recent
report
case
highli
order
monodispers
immunogen
notabl
extrem
stabil
found
induc
potent
immun
respons
emerg
concept
antigen
present
deliveri
exploit
sever
advantag
recombin
approach
codisplay
multipl
antigen
variant
singl
continu
surfac
antigen
variabl
target
influenza
ha
hiv
env
codisplay
could
provid
mechan
improv
breadth
vaccin
respons
focus
conserv
epitop
known
target
bnab
hypothesi
antigen
present
heterogen
array
would
alter
hierarchi
bcell
activ
provid
select
advantag
crossreact
b
cell
target
conserv
epitop
nanoparticlemedi
bcr
c
odisplay
codisplay
immunomodul
immunomodul
genet
deliveri
genet
deliveri
figur
antigen
display
deliveri
method
antigen
present
selfassembl
nanoparticl
either
natur
design
proven
robust
method
enhanc
humor
respons
upper
left
codisplay
relat
antigen
antigen
variant
color
uniqu
individu
nanoparticl
offer
customiz
strategi
alter
profil
vaccineinduc
antibodi
respons
upper
right
immunomodul
achiev
coloc
antigen
immunomodulatori
molecul
silver
blob
nanoparticl
lower
left
genet
deliveri
involv
administr
nucleic
acid
produc
immunogen
situ
offer
versatil
strategi
vaccin
product
may
also
improv
immunogen
lower
right
cluster
potenti
bival
bcr
ligat
contrast
b
cell
express
bcr
narrow
strainspecif
bind
would
receiv
advantag
offer
particul
antigen
would
rel
poorli
activ
type
mosaic
antigen
array
exist
natur
gener
surfac
selfassembl
protein
scaffold
report
recent
studi
multipl
monomer
ha
receptor
bind
domain
rbd
display
ferritin
gener
seri
antigen
variabl
nanoparticl
immunogen
intriguingli
breadth
immun
respons
induc
immunogen
correl
complex
mosaic
antigen
array
ie
number
antigen
distinct
rbd
display
nanoparticl
immunogen
superior
induc
cocktail
nanoparticl
individu
display
rbd
interest
determin
whether
concept
applic
antigen
divers
hardtohit
target
like
hiv
given
suitabl
scaffold
codisplay
could
also
use
present
heteromer
protein
complex
eg
human
cytomegaloviru
glycoprotein
pentam
multipl
protein
associ
pathogen
surfac
eg
herpesviru
gb
ghgl
context
codisplay
could
simplifi
vaccin
manufactur
character
addit
offer
enhanc
potenc
typic
obtain
multival
display
immunogen
target
certain
type
cell
induc
stronger
immun
respons
nontarget
counterpart
new
approach
modul
antigen
traffick
uptak
transport
manipul
size
surfac
chemistri
accessori
molecul
could
enhanc
antigen
avail
lymph
node
cognat
immun
cell
ie
b
cell
accessori
molecul
could
also
use
potenti
immun
respons
exploit
immun
signal
pathway
exampl
complement
classic
opsonin
recogn
complement
receptor
express
b
cell
follicular
dendrit
cell
b
cell
form
trimolecular
complex
signal
complex
amplifi
compens
low
level
bcr
signal
therefor
target
trimolecular
complex
may
act
molecular
adjuv
key
success
target
adjuv
coloc
targetingadjuv
molecul
surfac
vaccin
antigen
locat
provid
maxim
enhanc
antigenspecif
immun
respons
mitig
potenti
offtarget
effect
recent
develop
highli
customiz
nanoparticl
platform
capabl
codisplay
multipl
molecul
enabl
new
approach
modul
target
immun
signal
concept
still
infanc
need
rigor
test
nevertheless
near
futur
anticip
becom
possibl
reconstitut
immunolog
synaps
tailor
function
codisplay
varieti
costimulatori
inhibitori
regulatori
accessori
immunomodulatori
molecul
addit
vaccin
antigen
surfac
maxim
finetun
immun
stimul
design
immun
mrna
situ
translat
mani
potenti
advantag
method
antigen
deliveri
like
approach
genet
immun
dna
vaccin
viral
vector
product
antigen
deliv
mrna
mimic
replic
infecti
agent
three
key
way
first
antigen
provid
continu
period
time
contrast
bolu
antigen
deliv
proteinbas
subunit
vaccin
sever
recent
studi
demonstr
prolong
antigen
exposur
improv
magnitud
qualiti
vaccineinduc
respons
second
antigen
synthes
posttransl
modifi
process
present
b
cell
cell
way
natur
infect
includ
antigen
present
mhc
class
result
stronger
cellular
respons
typic
achiev
subunit
vaccin
third
variou
type
antigen
express
includ
cytoplasm
transmembran
secret
protein
well
engin
antigen
highli
immunogen
yet
incompat
manufactur
live
inactiv
wholepathogen
vaccin
support
viral
replic
eg
prefusionstabil
rsv
f
major
advantag
mrna
vaccin
genet
immun
platform
risk
infect
genom
integr
result
better
safeti
profil
manufactur
done
synthet
elimin
need
cell
cultur
potenti
contamin
anim
product
furthermor
manufactur
rapid
part
independ
sequenc
make
vaccin
modal
particularli
wellsuit
develop
rapid
respons
platform
protect
period
outbreak
pandem
final
unlik
viral
vector
antivector
immun
tend
issu
exist
deliveri
platform
could
help
enabl
repeat
dose
earli
approach
genet
immun
focus
dna
vaccin
viral
vector
due
concern
mrna
instabl
immunogen
recent
technolog
breakthrough
made
mrna
plausibl
commerci
vaccin
modal
decad
investig
basic
biolog
mrna
defin
sequenc
element
eg
utr
optim
strategi
eg
codon
optim
enabl
modul
intracellular
stabil
translat
effici
improv
potenc
also
obtain
minim
intrins
immunogen
nonendogen
mrna
trigger
innat
immun
respons
suppress
translat
encod
antigen
exampl
relat
discoveri
mrna
contain
modifi
nucleosid
pseudouridin
weaker
activ
rnasens
pattern
recognit
receptor
therefor
yield
higher
level
translat
protein
longer
period
time
cell
vivo
major
step
forward
subsequ
observ
mrna
prepar
free
doublestrand
rna
contamin
reduc
innat
immun
activ
increas
translat
effici
made
highlevel
express
deliv
antigen
without
undesir
immun
activ
possibl
antigenencod
viral
replicon
altern
approach
obtain
highlevel
antigen
express
addit
antigen
selfamplifi
mrna
encod
viral
replicas
make
copi
mrna
vector
lead
robust
antigen
product
potent
immun
respons
small
dose
mrna
one
potenti
drawback
selfamplifi
mrna
intrins
activ
innat
immun
like
contribut
potenc
elimin
control
import
aspect
mrna
vaccin
design
limit
durat
antigen
product
deliveri
system
transport
nucleic
acid
cytoplasm
requir
mrna
vaccin
effect
ex
vivo
load
dendrit
cell
pursu
cancer
vaccin
direct
immun
formul
mrna
like
viabl
approach
infecti
diseas
near
futur
although
substanti
progress
made
biolog
deliveri
gener
remain
unsolv
problem
mani
strategi
evalu
preclin
date
least
deliveri
platform
clinic
investig
mrna
vaccin
includ
uncomplex
mrna
mix
mrnaprotamin
complex
stimul
innat
immun
signal
mrnadecor
cation
lipid
nanoemuls
mrnaencapsid
lipid
nanoparticl
latter
system
pioneer
intraven
deliveri
sirna
therapeut
result
primarili
deliveri
liver
howev
intraderm
intramuscular
subcutan
administr
mrna
vaccin
formul
lipid
nanoparticl
result
robust
local
express
inject
site
encouragingli
mrna
vaccin
provid
impress
result
preclin
anim
model
data
begin
emerg
phase
clinic
trial
mrna
vaccin
infecti
diseas
clinic
trial
mrnamrnaprotamin
complex
vaccin
encod
rabi
viru
glycoprotein
induc
neutral
antibodi
virusspecif
cell
demonstr
accept
safeti
profil
howev
potenc
durabl
immun
respons
lower
preclin
anim
model
requir
use
needlefre
inject
devic
similarli
mrna
vaccin
modifi
nucleosid
formul
lipid
nanoparticl
encod
influenza
ha
induc
hai
titer
human
protect
threshold
similar
convent
commerci
avail
influenza
vaccin
yet
level
induc
anim
model
earli
data
encourag
suggest
addit
improv
mrna
vaccin
requir
realiz
full
potenti
promis
deliveri
platform
better
deliveri
system
innov
approach
trigger
innat
immun
without
sacrif
antigen
express
two
area
substanti
improv
could
made
improv
design
encod
antigensfor
exampl
use
selfassembl
nanoparticl
immunogen
discuss
earlieri
also
like
enhanc
perform
addit
technolog
goal
singleinject
subunit
vaccin
continu
drive
explor
control
releas
formul
base
synthet
biolog
polym
detail
reader
refer
excel
recent
review
one
hundr
year
spanish
flu
pandem
influenza
remain
massiv
burden
public
health
recent
year
method
develop
immunogen
design
result
signific
preclin
progress
toward
univers
influenza
vaccin
even
though
vaccin
yet
deploy
mani
recent
develop
approach
could
nonetheless
provid
substanti
improv
breadth
protect
exist
licens
vaccin
aim
univers
protect
vital
determin
best
possibl
way
redirect
immun
respons
toward
conserv
region
influenza
antigen
includ
rb
stem
ha
possibl
unexplor
region
neuraminidas
protein
new
approach
immunogen
design
enabl
develop
new
technolog
need
achiev
breadth
respons
conserv
region
requir
provid
univers
protect
better
knowledg
converg
antibodi
lineag
addit
experi
design
antigen
target
give
rise
bnab
expect
improv
current
approach
rigor
explor
new
method
antigen
display
use
selfassembl
scaffold
potenti
amplifi
respons
target
conserv
region
abil
design
novel
selfassembl
protein
platform
make
possibl
tailor
maxim
potenc
durabl
humor
respons
challeng
opportun
repres
novel
space
explor
conjunct
antigen
design
develop
deliveri
technolog
induc
cell
respons
mucos
immun
addit
target
antibodi
respons
respect
influenza
particular
essenti
understand
preexist
immun
influenc
respons
novel
immunogen
vaccin
design
process
best
accommod
effect
novel
strategi
technolog
develop
respons
challeng
present
univers
influenza
vaccin
applic
structurebas
design
vaccin
wide
rang
pathogen
incred
excit
time
field
vaccin
develop
predict
structurebas
designdriven
renaiss
recal
even
surpass
origin
golden
age
vaccin
supplementari
materi
avail
journal
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
